S&P 500   3,951.57 (+0.89%)
DOW   32,244.58 (+1.20%)
QQQ   305.97 (+0.20%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
S&P 500   3,951.57 (+0.89%)
DOW   32,244.58 (+1.20%)
QQQ   305.97 (+0.20%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
S&P 500   3,951.57 (+0.89%)
DOW   32,244.58 (+1.20%)
QQQ   305.97 (+0.20%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
S&P 500   3,951.57 (+0.89%)
DOW   32,244.58 (+1.20%)
QQQ   305.97 (+0.20%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
NASDAQ:OCDX

Ortho Clinical Diagnostics - OCDX Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$17.63
▼
$17.63
50-Day Range
$17.63
▼
$17.63
52-Week Range
$16.04
▼
$22.99
Volume
5,400 shs
Average Volume
1.24 million shs
Market Capitalization
$3.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

OCDX stock logo

About Ortho Clinical Diagnostics (NASDAQ:OCDX) Stock

Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.

Receive OCDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ortho Clinical Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

OCDX Stock News Headlines

March 18, 2023 | finance.yahoo.com
Clinical Diagnostics Global Market Report 2023: Sector to Reach $124.7 Billion by 2028 at a CAGR of 8.56%
February 25, 2023 | marketwatch.com
Clinical Diagnostics Mass Spectrometry Market Brief Analysis By Top Leading Companies
March 20, 2023 | Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
February 25, 2023 | marketwatch.com
Clinical Diagnostics Market 2023 is FASTEST-GROWING in [ Medical Devices & Consumables ] Sector till 2028
February 22, 2023 | marketwatch.com
Clinical Diagnostics Market Size in 2023 Business Forecast 2028 by Discovering LATEST TRENDS
February 18, 2023 | seekingalpha.com
ChitogenX announces $3.5M grant to advance ORTHO-R commercial development
January 25, 2023 | marketwatch.com
Clinical Diagnostics Mass Spectrometry Market 2023 : Future Developments, Key Vendors, Regional Analysis and Industry Scope by 2029
January 12, 2023 | finance.yahoo.com
The Worldwide Clinical Diagnostics Industry is Expected to Reach $93.6 Billion by 2027
March 20, 2023 | Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
November 2, 2022 | finance.yahoo.com
Dr. James S. Lewis II, Antibiotic Susceptibility Test Expert, Joins as Chair of Selux Diagnostics' Clinical Advisory Board
October 14, 2022 | finance.yahoo.com
Global Clinical Microbiology Instruments and Reagents Market Report 2022: Advancements in Molecular Diagnostics Drive Growth
September 23, 2022 | finance.yahoo.com
BrightInsight and bioMérieux Announce Partnership to Launch Clinical Digital Solutions for Diagnostics
May 7, 2022 | seekingalpha.com
Ortho Clinical Diagnostics Holdings PLC (OCDX) CEO Chris Smith on Q1 2022 Results - Earnings Call Transcript
May 5, 2022 | fool.com
Ortho Clinical Diagnostics Holdings plc (OCDX) Q1 2022 Earnings Call Transcript
May 5, 2022 | seekingalpha.com
Ortho Clinical Diagnostics Holdings plc 2022 Q1 - Results - Earnings Call Presentation
May 4, 2022 | finance.yahoo.com
Ortho Clinical Diagnostics (OCDX) Q1 Earnings Top Estimates
May 4, 2022 | seekingalpha.com
Ortho Clinical Diagnostics Non-GAAP EPS of $0.23 beats by $0.03, revenue of $495M misses by $12.41M
May 4, 2022 | finance.yahoo.com
Ortho Clinical Diagnostics Reports First Quarter 2022 Results
April 28, 2022 | finance.yahoo.com
Why Ortho Clinical (OCDX) Could Beat Earnings Estimates Again
April 27, 2022 | finance.yahoo.com
Ortho Clinical Diagnostics (OCDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
April 26, 2022 | finance.yahoo.com
Ortho Clinical Diagnostics Recognized with Fifth Prestigious Edison Award for Highly Accurate COVID-19 Solution
April 20, 2022 | finance.yahoo.com
Ortho Clinical Diagnostics to Report First Quarter 2022 Results on May 4, 2022
March 24, 2022 | finance.yahoo.com
Ortho Clinical (OCDX) Upgraded to Strong Buy: Here's What You Should Know
March 11, 2022 | finance.yahoo.com
Wall Street Analysts Predict a 58% Upside in Ortho Clinical (OCDX): Here's What You Should Know
March 9, 2022 | finance.yahoo.com
Ortho Clinical Diagnostics Wins Bronze Stevie® Award for Customer Service and Support
February 25, 2022 | finance.yahoo.com
Will Ortho Clinical (OCDX) Gain on Rising Earnings Estimates?
February 23, 2022 | finance.yahoo.com
Wall Street Analysts See a 54% Upside in Ortho Clinical (OCDX): Can the Stock Really Move This High?
See More Headlines
Receive OCDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ortho Clinical Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

OCDX Company Calendar

Last Earnings
11/03/2021
Today
3/20/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Diagnostic Substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCDX
CUSIP
N/A
CIK
1828443
Web
www.orthoclinicaldiagnostics.com
Phone
908-218-8000
Fax
N/A
Employees
4,800
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
21.77
P/E Growth
1.66
Net Income
$-54,300,000.00
Net Margins
-0.02%
Pretax Margin
1.38%
Return on Equity
41.71%
Return on Assets
5.10%

Debt

Debt-to-Equity Ratio
4.91
Current Ratio
1.89
Quick Ratio
1.29

Sales & Book Value

Annual Sales
$2.04 billion
Price / Sales
1.92
Cash Flow
$2.28 per share
Price / Cash Flow
7.73
Book Value
$1.99 per share
Price / Book
8.86

Miscellaneous

Outstanding Shares
222,585,000
Free Float
N/A
Market Cap
$3.92 billion
Optionable
Not Optionable
Beta
1.32

Key Executives

  • Mr. Christopher Michael SmithMr. Christopher Michael Smith (Age 59)
    Chairman & CEO
    Comp: $2.85M
  • Mr. Joseph M. Busky CPA (Age 54)
    Chief Financial Officer
    Comp: $607.06k
  • Mr. Michael A. SchlesingerMr. Michael A. Schlesinger (Age 63)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $879.13k
  • Mr. Michael S. Iskra (Age 52)
    Exec. VP of Commercial Excellence & Strategy
    Comp: $760.23k
  • Dr. Chockalingam Palaniappan Ph.D. (Age 57)
    Chief Innovation Officer
    Comp: $826.63k
  • Ms. Ariane Schiereck
    Chief Information Officer
  • Mr. Marwan Fathallah
    Head of Quality, Regulatory, Compliance, Clinical, Medical & Scientific Affairs
  • Mr. Gary Passman
    Head of People & Culture
  • Karen Taylor
    Head of Global Commercial Enablement
  • Mr. Warren Stone
    Head of Americas

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













OCDX Stock - Frequently Asked Questions

How were Ortho Clinical Diagnostics' earnings last quarter?

Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) issued its quarterly earnings results on Wednesday, November, 3rd. The company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.07. The company had revenue of $522.50 million for the quarter, compared to analysts' expectations of $485.36 million. Ortho Clinical Diagnostics had a positive trailing twelve-month return on equity of 41.71% and a negative net margin of 0.02%.

When did Ortho Clinical Diagnostics IPO?

(OCDX) raised $1.5 billion in an initial public offering (IPO) on Thursday, January 28th 2021. The company issued 70,000,000 shares at $20.00-$23.00 per share. J.P. Morgan, BofA Securities, Goldman Sachs, Barclays and Morgan Stanley acted as the underwriters for the IPO and Citigroup, Credit Suisse, UBS Investment Bank, Evercore ISI, Piper Sandler, ING, Macquarie Capital, Nomura, TCG Capital Markets, Drexel Hamilton, H.C. Wainwright & Co., Ramirez & Co. and Siebert Williams Shank were co-managers.

What is Ortho Clinical Diagnostics' stock symbol?

Ortho Clinical Diagnostics trades on the NASDAQ under the ticker symbol "OCDX."

What is Ortho Clinical Diagnostics' stock price today?

One share of OCDX stock can currently be purchased for approximately $17.63.

How much money does Ortho Clinical Diagnostics make?

Ortho Clinical Diagnostics (NASDAQ:OCDX) has a market capitalization of $3.92 billion and generates $2.04 billion in revenue each year. The company earns $-54,300,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis.

How many employees does Ortho Clinical Diagnostics have?

The company employs 4,800 workers across the globe.

How can I contact Ortho Clinical Diagnostics?

Ortho Clinical Diagnostics' mailing address is 1001 ROUTE 202, RARITAN NJ, 08869. The official website for the company is www.orthoclinicaldiagnostics.com. The company can be reached via phone at 908-218-8000 or via email at ir@orthoclinicaldiagnostics.com.

This page (NASDAQ:OCDX) was last updated on 3/20/2023 by MarketBeat.com Staff